Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer - Annals of Oncology
Confirmatory Overall Survival Analysis of CLEOPATRA | Research To Practice
Confirmatory Overall Survival Analysis of CLEOPATRA | Research To Practice
CLEOPATRA: Survival With Dual HER2 Blockade 'Unprecedented' - The ASCO Post
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial - Annals of Oncology
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
PERJETA® (pertuzumab) HER2+ Metastatic Trial Design | HCP
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar
Real-World Analysis of THP in mBC Shows Similar Survival, Safety Outcomes to CLEOPATRA Trial
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
Confirmatory Overall Survival Analysis of CLEOPATRA | Research To Practice
HER2 Therapies - HER2+ MBC - Module - HER2+ MBC Care - Oncology - Clinical Care Options
1 RESPONSE TO THE PUBLICATION OF THE CLEOPATRA CLINICAL TRIAL PAPER Executive Summary If a patient does not take a treatment th
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open
HER2-positive advanced breast cancer treatment in 2020 - Cancer Treatment Reviews
Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download
Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram
Nadine Ezer Clinical Trial Monitor Roche - ppt download
CLEOPATRA Protocol review & OS 분석결과. Study Title A Phase III, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Evaluate the Efficacy and. - ppt download
